Supplement shows promise for diabetes blood flow issues
NCT ID NCT04557228
First seen May 09, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This study tested whether a dietary supplement called phosphatidylserine can improve blood flow in people with type 2 diabetes. 36 adults took either the supplement or a placebo for 4 weeks. Researchers measured blood flow in the leg and arm to see if the supplement helped blood vessels work better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Missouri- NextGen Clinical Translational Science Unit
Columbia, Missouri, 65212, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
phosphatidylserine (a dietary supplement)
What this could lead to
If it works, this could point toward a simple dietary supplement to improve blood vessel function in people with type 2 diabetes.
What could go wrong
This was a small, early-stage trial with only 36 participants. The supplement may not show meaningful benefits, and results may not apply to everyone with diabetes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.